<unk>  is indicated for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; and adults with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Umbralisib
Vagisil
Snoezelen
Tezacaftor
Burapitant
Beractant
Androvax
Furegrelate